Atlas Trials

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Clinical trial NCT02091752 · TERMINATED

Trial details

NCT number
NCT02091752
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Myelofibrosis
Start date
2014-09-01
Primary completion
2015-02-01
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.